

# **Indigo Paints Ltd.**

Outperforming the industry amidst demand headwinds

In Q2FY25, Indigo Paints Ltd (IPL) achieved topline growth of ~7.4% on a YoY basis, outperforming the industry by ~7.3% despite challenging market conditions. The Emulsion segment reported volume growth of ~7.2% on a YoY basis, with realizations increasing by ~30 bps on a YoY basis, supported by price hikes during the quarter. The Enamels and Wood Coatings segments saw volume growth of 4.3% on a YoY basis, though realizations declined by ~70 bps on a YoY basis. In the Cement and Putty segment, volume grew by ~2.8% on a YoY basis and realizations rose by ~20 bps on a YoY basis. The Primers, Distempers, and Others segment posted the strongest performance, with ~7.1% volume growth on a YoY basis and a significant realization increase of ~6.6% on a YoY basis, driven by higher contributions from WPCC products. The subsidiary Apple Chemie recorded a growth rate of ~27.7% on a YoY basis, with margins affected by an adverse product mix.

#### Outperforming the industry amid market challenges

During the quarter, the Company achieved a strong topline growth of  $^{\sim}$ 7.4% on a YoY basis, significantly outpacing the industry's flat growth of 0.1% on a YoY basis. In contrast, key competitors in the decorative paint industry, including Asian Paints Ltd. (APL) and Berger Paints India Ltd. (BPIL), posted subdued results, with APL experiencing a decline of  $^{\sim}$ 5.3% on a YoY basis and BPIL remaining almost flat at  $^{\sim}$ 0.3% on a YoY basis. This slowdown in industry demand was primarily driven by weak consumer sentiment, prolonged rainfall, and regional flooding in certain geographies.

#### Anticipated improvement in market conditions

Market conditions are expected to improve, with realizations benefiting from price hikes implemented in H1FY25 and a recovery in demand sentiment in the decorative paint industry anticipated in H2FY25, driven by seasonal trends. The Company's growth will also be supported by the launch of a new, differentiated product, an increased share of WPCC products, and an expanded distribution network. Additionally, the Company is focusing on strengthening its presence in Tier 1 and Tier 2 cities, backed by a larger sales force and enhanced digital customer engagement initiatives.

#### View & Valuation

Due to weak demand and rising raw material costs, profitability was impacted. However, the effect was less severe than industry peers, suggesting gains in both – the industry's sales and profit share. For FY25, we anticipate growth of ~10%, driven by improved prospects observed at the start of H2. Additionally, we expect positive demand sentiment to continue to benefit IPL's expansionary initiatives. Consequently, we anticipate a topline growth of ~15% in FY26. Subsequently, we have revised our estimates and maintained a NEUTRAL rating on IPL. Given IPL's outperformance in a stagnant growth market, we have revised the PE multiple from ~42x to 44x on FY26E EPS, resulting in a target price of ~Rs. 1,552, which suggests a potential upside of about 4%.

## 12th November 2024

# **NEUTRAL**

CMP Rs. 1,489

TARGET Rs. 1,552 (+4%)


#### **Company Data**

Bloomberg Code	INDIGOPNIN
MCAP (Rs. Mn)	71,472
O/S Shares (Mn)	48
52w High/Low	1,720/1,253
Face Value (Rs.)	10
Liquidity (3M) (Rs. Mn)	938

#### Shareholding Pattern %

	Sep 24	Jun 24	Mar 24
Promoters	53.9	53.9	53.9
FIIs	12.3	8.3	7.7
DIIs	16.1	1.1	2.0
Non- Institutional	17.6	36.7	36.4

#### **IPL vs Nifty**



Nov, 21 Nov, 22 Nov, 23 Nov		Nov, 22	Nov, 23	Nov, 2
-----------------------------	--	---------	---------	--------

Source: Keynote Capitals Ltd.

#### **Key Financial Data**

-,			
(Rs Bn)	FY24	FY25E	FY26E
Revenue	13	14	16
EBITDA	2	2	3
Net Profit	1	1	2
<b>Total Assets</b>	13	14	16
ROCE (%)	17%	14%	15%
ROE (%)	18%	14%	15%

Source: Company, Keynote Capitals Ltd.

Karan Galaiya, Research Analyst Karan@keynotecapitals.net






## **Q2 FY25 Result Update**

Result Highlights (Rs. Mn)


Particulars	Q2 FY25	Q2 FY24	Change % (Y-o-Y)	Q1 FY25	Change % (Q-o-Q)	H1 FY25	H1 FY24	Change % (Y-o-Y)	FY24
Revenue	2,995	2,790	7%	3,110	-4%	6,105	5,674	8%	13,061
Gross Profit	1,309	1,271	3%	1,449	-10%	2,758	2,636	5%	6,222
Gross Profit %	44%	46%	-186 bps	47%	-290 bps	45%	46%	-128 bps	48%
Employee Cost	297	255	17%	302	-2%	599	498	20%	995
Other Expenses	597	595	0%	673	-11%	1,270	1,226	4%	2,846
EBITDA	415	421	-1%	474	-12%	889	912	-3%	2,381
EBITDA %	14%	15%	-124 bps	15%	-138 bps	15%	16%	-152 bps	18%
Depreciation	154	113	36%	152	1%	306	214	43%	516
EBIT	261	308	-15%	321	-19%	583	699	-17%	1,865
Finance Cost	7	6	28%	6	12%	13	10	29%	21
Other Income	51	32	61%	42	22%	93	70	33%	142
PBT	305	335	-9%	357	-14%	662	758	-13%	1,986
Tax	83	81	2%	90	-8%	173	190	-9%	498
PAT	223	253	-12%	267	-17%	489	568	-14%	1,488
EPS	4.7	5.3	-11%	5.5	-14%	10.2	11.8	-13%	30.9

Source: Company, Keynote Capitals Ltd.

## **Quarterly Business Progression**





Emulsions (YoY growth %)




Source: Company, Keynote Capitals Ltd.









Active tinting machine



**Active Dealer Count** 



IPL vs Industry Growth (YoY growth %)



Source: Company, Keynote Capitals Ltd.

## Indigo Paints Ltd. | Quarterly Update



#### **Q2 FY25 Conference Call Takeaways**

#### **General Highlights**

- The Company achieved its sixth consecutive quarter of industry-leading growth in Q2FY25, despite challenging market conditions over the past three quarters.
- The Company experienced a slight decrease in gross margins on a YoY basis, primarily due to price reductions implemented in H2FY24. Margins were further pressured by rising raw material costs, soft demand, and increased trade channel discounts aimed at expanding market share. Although a modest price increase was introduced in H1FY25, margins remain lower on a YoY basis.
- The primers and distempers segment saw strong value growth in Q2FY25, driven by high demand for WPCC products, which continue to increase their contribution to revenue. These products are priced between economy and premium emulsion paints, fueling the strong value growth.
- In the putty segment, the Company maintained positive margins in Q2FY25 despite industry-wide price pressure, prioritizing quality and stable pricing to attract value-conscious customers and support longterm growth.
- During the quarter, ACIL's margins were impacted despite strong volume growth due to a shift in product mix and project delays caused by excessive rainfall. However, a strong recovery was observed in October 2024, and margins are expected to normalize from Q3FY25 onwards.
- The sequential increase in depreciation was mainly due to the new plant in Tamil Nadu, commissioned in Q2FY24. This higher depreciation rate will be incorporated into the base from Q3FY25, with no expected divergence between PAT and EBIT from Q3FY25 onwards.

#### Distribution

- The Company continues expanding its distribution network, increasing dealer throughput, and growing the tinting machine population. Its twoyear focus on Tier 1 and Tier 2 cities has shown excellent results, overcoming initial challenges of brand loyalty, with a significant share of sales and tinting machines now coming from these cities.
- About 55% of dealers have tinting machines, as only emulsions primarily require them, while other products do not. The Company aims to increase the tinting machine-to-dealer ratio to 75% in the medium term
- In Q2, A&SP expense as a % of revenue continued to decline, with this
  trend expected to persist. The Company has shifted from primarily TV
  to digital media spending to boost brand awareness, adapting to
  growing digital consumption and declining TV viewership.
- The Company expects to increase its throughput per dealer by deploying tinting machines to boost sales, expanding its wholesale dealer base, and loyalty programs.



## Indigo Paints Ltd. | Quarterly Update

- A major differentiated product is awaiting regulatory clearance and is expected to go live in the next 3-4 months. The Company has invested significant time in developing this product, which is anticipated to be a valuable addition to its strong portfolio of differentiated offerings.
- On the capex front, civil work is progressing well at both Jodhpur plants. The water-based plant is expected to go live in Q2FY26, while the solvent-based plant is scheduled for Q4FY25 or Q1FY26. Additionally, the brownfield expansion of the putty plant in Jodhpur is expected to be completed by Q4FY25. No significant additional capex is expected in the next 3-4 years, considering the expected demand outlook.



# Indigo Paints Ltd. | Quarterly Update

## **Financial Statement Analysis**

Income Statement					
Y/E Mar, Rs. Mn	FY23	FY24	FY25E	FY26E	FY27E
Net Sales	10,733	13,061	14,302	16,447	19,407
Growth %	18%	22%	10%	15%	18%
Raw Material Expenses	5,952	6,839	7,508	8,552	10,092
Employee Expenses	731	995	1,359	1,530	1,747
Other Expenses	2,235	2,846	3,075	3,536	4,173
EBITDA	1,815	2,381	2,360	2,829	3,396
Growth %	33%	31%	-1%	20%	20%
Margin%	17%	18%	17%	17%	18%
Depreciation	343	516	653	673	696
EBIT	1,472	1,865	1,706	2,156	2,700
Growth %	41%	27%	-8%	26%	25%
Margin%	14%	14%	12%	13%	14%
Interest Paid	14	21	27	27	27
Other Income & exceptional	101	142	186	200	200
PBT	1,559	1,986	1,865	2,329	2,874
Tax	239	498	466	582	718
PAT	1,319	1,488	1,399	1,747	2,155
Others (Minorities, Associates)	0	15	-58	-68	-68
Net Profit	1,319	1,503	1,341	1,679	2,087
Growth %	57%	14%	-11%	25%	24%
Shares (Mn)	47.6	47.6	47.6	47.6	47.6
EPS	27.73	30.94	28.18	35.28	43.86

Balance Sheet					
Y/E Mar, Rs. Mn	FY23	FY24	FY25E	FY26E	FY27E
Cash, Cash equivalents & Bank	488	329	2,054	3,955	6,219
Current Investments	1,317	1,667	1,667	1,667	1,667
Debtors	2,001	2,231	2,360	2,796	3,299
Inventory	1,177	1,706	1,877	2,138	2,523
Short Term Loans & Advances	187	265	265	265	265
Other Current Assets	18	48	48	48	48
Total Current Assets	5,187	6,246	8,271	10,869	14,021
Net Block & CWIP	5,156	6,085	5,646	5,220	4,815
Long Term Investments	0	0	0	0	0
Other Non-current Assets	273	373	373	373	373
Total Assets	10,616	12,704	14,290	16,462	19,209
Creditors	1,991	2,290	2,419	2,776	3,300
Provision	216	36	36	36	36
Short Term Borrowings	0	8	8	8	8
Other Current Liabilities	434	527	527	527	527
Total Current Liabilities	2,641	2,861	2,991	3,348	3,872
Long Term Debt	0	15	15	15	15
Deferred Tax Liabilities	69	200	200	200	200
Other Long Term Liabilities	145	606	606	606	606
Total Non Current Liabilities	214	821	821	821	821
Paid-up Capital	476	476	476	476	476
Reserves & Surplus	7,285	8,545	9,944	11,691	13,846
Shareholders' Equity	7,761	9,021	10,420	12,167	14,322
Non Controlling Interest	0	0	58	126	194
Total Equity & Liabilities	10,616	12,704	14,290	16,462	19,209

**Cash Flow** Y/E Mar, Rs. Mn FY23 FY24 FY25E FY26E FY27E Pre-tax profit 1,559 1,986 1,865 2,329 2,874 591 Adjustments 351 494 553 568 Change in Working Capital -505 -377 -171 -340 -364 Total Tax Paid -244 -593 -466 -582 -718 Cash flow from operating 1,161 1,510 1,781 1,975 2,382 Activities -1,970 -1,041 -215 -247 -291 Net Capital Expenditure Change in investments 1,100 -506 0 0 0 Other investing activities 25 30 186 200 200 Cash flow from investing -1,517 -29 -47 -91 -844 activities Equity raised / (repaid) 0 0 0 0 0 0 -64 0 0 0 Debt raised / (repaid) -143 0 0 0 Dividend (incl. tax) -167 Other financing activities -58 -2 -27 -27 -27 Cash flow from financing -201 -232 -27 -27 -27 activities Net Change in cash 116 1,725 2,264 -239 1,901

Valuation Ratios					
	FY23	FY24	FY25E	FY26E	FY27E
Per Share Data					
EPS	28	31	28	35	44
Growth %	57%	12%	-9%	25%	24%
Book Value Per Share	163	190	220	258	305
Return Ratios					
Return on Assets (%)	13%	13%	10%	11%	12%
Return on Equity (%)	19%	18%	14%	15%	16%
Return on Capital Employed (%)	19%	17%	14%	15%	16%
Turnover Ratios					
Asset Turnover (x)	1.1	1.1	1.1	1.1	1.1
Sales / Gross Block (x)	3.0	2.3	1.9	2.1	2.4
Working Capital / Sales (x)	27%	23%	30%	39%	46%
Receivable Days	63	59	59	57	57
Inventory Days	72	77	87	86	84
Payable Days	123	106	112	108	106
Working Capital Days	13	30	34	35	36
Liquidity Ratios					
Current Ratio (x)	2.0	2.2	2.8	3.2	3.6
Interest Coverage Ratio (x)	114.3	94.6	69.7	88.3	108.8
Total Debt to Equity	0.0	0.0	0.0	0.0	0.0
Net Debt to Equity	-0.1	0.0	-0.2	-0.3	-0.4
Valuation					
PE (x)	36.4	32.6	44.6	35.6	28.7
Earnings Yield (%)	3%	3%	2%	3%	3%
Price to Sales (x)	4.5	3.7	4.2	3.6	3.1
Price to Book (x)	6.2	6.6	5.7	4.9	4.2
EV/EBITDA (x)	26.2	25.0	25.2	21.0	17.5
EV/Sales (x)	4.4	4.6	4.2	3.6	3.1

Source: Company, Keynote Capitals Ltd. Estimates

## **KEYNOTE Rating History**

Date	Rating	Market Price at Recommendation	Upside/Downside
4 <sup>th</sup> July 2024	BUY	1,381	+15.4%
12 <sup>th</sup> August 2024	NEUTRAL	1,433	+2%
12 <sup>th</sup> November 2024	NEUTRAL	1,489	+4%





## **Rating Methodology**

Rating	Criteria
BUY	Expected positive return of > 10% over 1-year horizon
NEUTRAL	Expected positive return of > 0% to < 10% over 1-year horizon
REDUCE	Expected return of < 0% to -10% over 1-year horizon
SELL	Expected to fall by >10% over 1-year horizon
NOT RATED (NR)/UNDER REVIEW (UR)/COVERAGE SUSPENDED (CS)	Not covered by Keynote Capitals Ltd/Rating & Fair value under Review/Keynote Capitals Ltd has suspended coverage

#### **Disclosures and Disclaimers**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Keynote Capitals Ltd. (KCL) is a SEBI Registered Research Analyst having registration no. INH000007997. KCL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. Details of associate entities of Keynote Capitals Limited are available on the website at <a href="https://www.keynotecapitals.com/associate-entities/">https://www.keynotecapitals.com/associate-entities/</a>

KCL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of KCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

KCL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that KCL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Details of pending Enquiry Proceedings of KCL are available on the website at <a href="https://www.keynotecapitals.com/pending-enquiry-proceedings/">https://www.keynotecapitals.com/pending-enquiry-proceedings/</a>

A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of KCL or its associates maintains arm's length distance with Research Team as all the activities are segregated from KCL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KCL & its group companies to registration or licensing requirements within such jurisdictions. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

#### Specific Disclosure of Interest statement for subjected Scrip in this document:

Financial Interest of Research Entity [KCL] and its associates; Research Analyst and its Relatives	NO
Any other material conflict of interest at the time of publishing the research report by Research Entity [KCL] and its associates; Research Analyst and its Relatives	NO
Receipt of compensation by KCL or its Associate Companies from the subject company covered for in the last twelve months; Managing/co-managing public offering of securities in the last twelve months; Receipt of compensation towards Investment banking/merchant banking/brokerage services in the last twelve months; Products or services other than those above in connection with research report in the last twelve months; Compensation or other benefits from the subject company or third party in connection with the research report in the last twelve months.	NO
Whether covering analyst has served as an officer, director or employee of the subject company covered	NO
Whether the KCL and its associates has been engaged in market making activity of the Subject Company	NO
Whether the Research Entity [KCL] and its associates; Research Analyst and its Relatives, have actual/beneficial ownership of 1% or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance.	NO





#### The associates of KCL may have:

- financial interest in the subject company
- -actual/beneficial ownership of 1% or more securities in the subject company
- -received compensation/other benefits from the subject company in the past 12 months
- -other potential conflict of interests with respect to any recommendation and other related information and opinions.; however, the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of KCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- -acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- -be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- -received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of KCL has not received any compensation or other benefits from third party in connection with the research report.

Above disclosures includes beneficial holdings lying in demat account of KCL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of KCL for other purposes (i.e. holding client securities, collaterals, error trades etc.). KCL also earns DP income from clients which are not considered in above disclosures.

#### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### **Terms & Conditions:**

This report has been prepared by KCL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KCL. The report is based on the facts, figures and information that are believed to be true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KCL will not treat recipients as customers by virtue of their receiving this report

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative product as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. KCL, its associates, their directors and the employees may from time to time, effect or have affected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. KCL, its associates, their directors and the employees may from time to time invest in any discretionary PMS/AIF Fund and those respective PMS/AIF Funds may affect or have effected any transaction in for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of KCL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KCL to any registration or licensing requirement within such jurisdiction.





The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt KCL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold KCL or any of its affiliates or employees responsible for any such misuse and further agrees to hold KCL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

## Keynote Capitals Limited (CIN: U67120MH1995PLC088172)

Compliance Officer: Mr. Jairaj Nair; Tel: 022-68266000; email id: jairaj@keynoteindia.net

Registered Office: 9th Floor, The Ruby, Senapati Bapat Marg, Dadar West, Mumbai – 400028, Maharashtra. Tel: 022 – 68266000.

SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD): INZ000241530; DP: CDSL- IN-DP-238-2016; Research Analyst: INH000007997

For any complaints email at kcl@keynoteindia.net

General Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on <a href="https://www.keynotecapitals.com">www.keynotecapitals.com</a>; Investment in securities market are subject to market risks, read all the related documents carefully before investing.